255 related articles for article (PubMed ID: 25151963)
21. Development of a Self-Assembled Nanoparticle Formulation of Orlistat, Nano-ORL, with Increased Cytotoxicity against Human Tumor Cell Lines.
Hill TK; Davis AL; Wheeler FB; Kelkar SS; Freund EC; Lowther WT; Kridel SJ; Mohs AM
Mol Pharm; 2016 Mar; 13(3):720-8. PubMed ID: 26824142
[TBL] [Abstract][Full Text] [Related]
22. Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex.
Brugarolas J; Lei K; Hurley RL; Manning BD; Reiling JH; Hafen E; Witters LA; Ellisen LW; Kaelin WG
Genes Dev; 2004 Dec; 18(23):2893-904. PubMed ID: 15545625
[TBL] [Abstract][Full Text] [Related]
23. Overexpression of fatty acid synthase in Middle Eastern epithelial ovarian carcinoma activates AKT and Its inhibition potentiates cisplatin-induced apoptosis.
Uddin S; Jehan Z; Ahmed M; Alyan A; Al-Dayel F; Hussain A; Bavi P; Al-Kuraya KS
Mol Med; 2011; 17(7-8):635-45. PubMed ID: 21442130
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of fatty acid synthase induces endoplasmic reticulum stress in tumor cells.
Little JL; Wheeler FB; Fels DR; Koumenis C; Kridel SJ
Cancer Res; 2007 Feb; 67(3):1262-9. PubMed ID: 17283163
[TBL] [Abstract][Full Text] [Related]
25. Regulation of mTOR and cell growth in response to energy stress by REDD1.
Sofer A; Lei K; Johannessen CM; Ellisen LW
Mol Cell Biol; 2005 Jul; 25(14):5834-45. PubMed ID: 15988001
[TBL] [Abstract][Full Text] [Related]
26. Tumor growth retardation and chemosensitizing action of fatty acid synthase inhibitor orlistat on T cell lymphoma: implication of reconstituted tumor microenvironment and multidrug resistance phenotype.
Kant S; Kumar A; Singh SM
Biochim Biophys Acta; 2014 Jan; 1840(1):294-302. PubMed ID: 24060750
[TBL] [Abstract][Full Text] [Related]
27. Ovarian Cancer-Intrinsic Fatty Acid Synthase Prevents Anti-tumor Immunity by Disrupting Tumor-Infiltrating Dendritic Cells.
Jiang L; Fang X; Wang H; Li D; Wang X
Front Immunol; 2018; 9():2927. PubMed ID: 30619288
[TBL] [Abstract][Full Text] [Related]
28. The fatty acid synthase inhibitor orlistat reduces experimental metastases and angiogenesis in B16-F10 melanomas.
Seguin F; Carvalho MA; Bastos DC; Agostini M; Zecchin KG; Alvarez-Flores MP; Chudzinski-Tavassi AM; Coletta RD; Graner E
Br J Cancer; 2012 Sep; 107(6):977-87. PubMed ID: 22892389
[TBL] [Abstract][Full Text] [Related]
29. Fatty acid synthase inhibition with Orlistat promotes apoptosis and reduces cell growth and lymph node metastasis in a mouse melanoma model.
Carvalho MA; Zecchin KG; Seguin F; Bastos DC; Agostini M; Rangel AL; Veiga SS; Raposo HF; Oliveira HC; Loda M; Coletta RD; Graner E
Int J Cancer; 2008 Dec; 123(11):2557-65. PubMed ID: 18770866
[TBL] [Abstract][Full Text] [Related]
30. Orlistat as a FASN inhibitor and multitargeted agent for cancer therapy.
Schcolnik-Cabrera A; Chávez-Blanco A; Domínguez-Gómez G; Taja-Chayeb L; Morales-Barcenas R; Trejo-Becerril C; Perez-Cardenas E; Gonzalez-Fierro A; Dueñas-González A
Expert Opin Investig Drugs; 2018 May; 27(5):475-489. PubMed ID: 29723075
[TBL] [Abstract][Full Text] [Related]
31. Cell-type-dependent regulation of mTORC1 by REDD1 and the tumor suppressors TSC1/TSC2 and LKB1 in response to hypoxia.
Wolff NC; Vega-Rubin-de-Celis S; Xie XJ; Castrillon DH; Kabbani W; Brugarolas J
Mol Cell Biol; 2011 May; 31(9):1870-84. PubMed ID: 21383064
[TBL] [Abstract][Full Text] [Related]
32. Fatty acid synthase is a key target in multiple essential tumor functions of prostate cancer: uptake of radiolabeled acetate as a predictor of the targeted therapy outcome.
Yoshii Y; Furukawa T; Oyama N; Hasegawa Y; Kiyono Y; Nishii R; Waki A; Tsuji AB; Sogawa C; Wakizaka H; Fukumura T; Yoshii H; Fujibayashi Y; Lewis JS; Saga T
PLoS One; 2013; 8(5):e64570. PubMed ID: 23741342
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of fatty acid synthase by luteolin post-transcriptionally down-regulates c-Met expression independent of proteosomal/lysosomal degradation.
Coleman DT; Bigelow R; Cardelli JA
Mol Cancer Ther; 2009 Jan; 8(1):214-24. PubMed ID: 19139131
[TBL] [Abstract][Full Text] [Related]
34. FABP5 suppresses colorectal cancer progression via mTOR-mediated autophagy by decreasing FASN expression.
Ye M; Hu C; Chen T; Yu P; Chen J; Lu F; Xu L; Zhong Y; Yan L; Kan J; Bai J; Li X; Tian Y; Tang Q
Int J Biol Sci; 2023; 19(10):3115-3127. PubMed ID: 37416772
[TBL] [Abstract][Full Text] [Related]
35. Activating transcription factor 4 and CCAAT/enhancer-binding protein-beta negatively regulate the mammalian target of rapamycin via Redd1 expression in response to oxidative and endoplasmic reticulum stress.
Jin HO; Seo SK; Woo SH; Kim ES; Lee HC; Yoo DH; An S; Choe TB; Lee SJ; Hong SI; Rhee CH; Kim JI; Park IC
Free Radic Biol Med; 2009 Apr; 46(8):1158-67. PubMed ID: 19439225
[TBL] [Abstract][Full Text] [Related]
36. Mammalian target of rapamycin complex 1 (mTORC1) enhances bortezomib-induced death in tuberous sclerosis complex (TSC)-null cells by a c-MYC-dependent induction of the unfolded protein response.
Babcock JT; Nguyen HB; He Y; Hendricks JW; Wek RC; Quilliam LA
J Biol Chem; 2013 May; 288(22):15687-98. PubMed ID: 23612979
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of FASN reduces the synthesis of medium-chain fatty acids in goat mammary gland.
Zhu JJ; Luo J; Wang W; Yu K; Wang HB; Shi HB; Sun YT; Lin XZ; Li J
Animal; 2014 Sep; 8(9):1469-78. PubMed ID: 24909980
[TBL] [Abstract][Full Text] [Related]
38. Dexamethasone represses signaling through the mammalian target of rapamycin in muscle cells by enhancing expression of REDD1.
Wang H; Kubica N; Ellisen LW; Jefferson LS; Kimball SR
J Biol Chem; 2006 Dec; 281(51):39128-34. PubMed ID: 17074751
[TBL] [Abstract][Full Text] [Related]
39. Glucocorticoid elevation of dexamethasone-induced gene 2 (Dig2/RTP801/REDD1) protein mediates autophagy in lymphocytes.
Molitoris JK; McColl KS; Swerdlow S; Matsuyama M; Lam M; Finkel TH; Matsuyama S; Distelhorst CW
J Biol Chem; 2011 Aug; 286(34):30181-9. PubMed ID: 21733849
[TBL] [Abstract][Full Text] [Related]
40. Growth control under stress: mTOR regulation through the REDD1-TSC pathway.
Ellisen LW
Cell Cycle; 2005 Nov; 4(11):1500-02. PubMed ID: 16258273
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
